Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Cancer, Bladder Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | June 2009 |
| End Date: | May 2012 |
Phase I Dose-escalation Trial of CP-675,206 (Tremelimumab, Anti-CTLA-4 Monoclonal Antibody) for Patients With BCG-resistant Localized Transitional Cell Carcinoma of the Bladder
The purpose of this study is to find out the highest safe dose of the investigational drug
CP-675,206 when given in combination with BCG therapy to patients who have experienced
recurrent superficial bladder cancer after standard BCG treatment.
In addition, the study will look to see if taking CP 675,206 generates an immune response
and evaluate how the drug affects superficial bladder cancer.
We found this trial at
1
site
Click here to add this to my saved trials
